Tyler King, MD
Hospitalist · Little Rock, ARNPI 1811287857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boehringer Ingelheim at 34.9% of the total. Reporting peaked in 2024 at $85 and has fallen 82.8% since, to $15 in 2025.
Across 15 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$106
- AstraZeneca$88
- Nabriva Therapeutics, PLC$28
- Boston Scientific$24
- Johnson & Johnson$17
- AbbVie$15
- plus $26 from 2 others
What the payments were for
- Food & beverage$303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $106 |
| AstraZeneca | 4 | $88 |
| Nabriva Therapeutics, PLC | 1 | $28 |
| Boston Scientific | 1 | $24 |
| Johnson & Johnson | 1 | $17 |
| AbbVie | 1 | $15 |
| Enterra Medical, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$303 in reported general payments places this provider in the 75th percentile of 125 hospitalist providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $24,110 |
| OzempicSemaglutide | 11 | $9,842 |
| Pantoprazole Sodium | 27 | $210 |
| Prednisone | 27 | $153 |
| Levofloxacin | 50 | $144 |
| Atorvastatin Calcium | 12 | $106 |
| Metoprolol Succinate | 12 | $91 |
| Amlodipine Besylate | 21 | $90 |
| Furosemide | 11 | $31 |
| Lisinopril | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Little Rock
- Chandra DasariLittle Rock$829
- Abul KamalLittle Rock$417
- Tulika PandeyLittle Rock$397
- Matthew LawLittle Rock$339
- Bilal SadiqLittle Rock$221
- Khalid SawalhaLittle Rock$218
- Heather BorchertLittle Rock$157
- Alexander NavarroHot Springs$2K
- Jonathan HoltJonesboro$1K
- Michael BoldingFayetteville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.